identif
novel
b
coronaviru
ncov
caus
agent
sever
respiratori
ill
human
origin
saudi
arabia
qatar
jordan
rais
concern
possibl
coronaviru
pandem
similar
sarscov
definit
treatment
regimen
never
thoroughli
evalu
coronaviru
infect
urgent
need
rapidli
identifi
potenti
therapeut
address
futur
case
ncov
determin
intervent
strategi
effect
ribavirin
ncov
isol
replic
vero
cell
evalu
sensit
ribavirin
alon
vero
cell
rel
high
concentr
howev
combin
lower
concentr
ribavirin
achiev
compar
endpoint
thu
combin
ribavirin
alreadi
commonli
use
clinic
may
use
patient
manag
event
futur
ncov
infect
novel
b
coronaviru
ncov
identifi
etiolog
agent
confirm
case
death
sever
respiratori
ill
occasion
renal
failur
patient
saudi
arabia
qatar
jordan
unit
kingdom
complet
genom
sequenc
determin
new
viru
close
relat
two
asian
bat
betacoronavirus
lineag
c
make
ncov
first
lineag
c
betacoronaviru
known
infect
human
humantohuman
transmiss
assum
less
extens
compar
sarscov
three
case
saudi
arabia
within
one
famili
sever
healthcar
worker
care
two
case
jordan
classifi
probabl
case
moreov
recent
cluster
case
two
three
case
histori
travel
middl
east
suspect
result
humantohuman
transmiss
within
uk
famili
member
travel
histori
saudi
arabia
pakistan
would
suggest
humantohuman
transmiss
occur
close
contact
set
presum
sporad
natur
appar
unlink
index
case
three
differ
albeit
geograph
proxim
countri
close
relationship
asian
bat
coronavirus
suggest
sourc
ncov
zoonot
despit
limit
inform
new
viru
determin
contrast
sarscov
use
angiotensinconvert
enzym
gain
entri
cell
ncov
use
dipeptidyl
peptidas
function
receptor
find
may
import
requir
thought
partial
respons
pathogen
sarscov
also
serv
one
factor
may
limit
spread
humantohuman
pathogenesi
ncov
could
significantli
differ
previous
studi
coronavirus
abil
predict
whether
viru
like
result
larger
epidem
even
pandem
occur
sarscov
unknown
rapid
identif
therapeut
high
prioriti
current
specif
therapi
vaccin
ncov
result
diseas
sever
high
casefat
rate
clinic
experi
sar
suggest
number
intervent
includ
ribavirin
without
corticosteroid
ribavirin
proteas
inhibitor
interferon
corticosteroid
may
improv
outcom
definit
treatment
regimen
clearli
establish
address
effect
vitro
two
antivir
drug
ribavirin
attempt
identifi
therapeut
approach
immedi
util
clinic
benefit
futur
case
subject
area
antivir
sar
viru
antivir
agent
viral
infect
novel
b
coronaviru
ncov
identifi
etiolog
agent
confirm
case
death
sever
respiratori
ill
occasion
renal
failur
patient
saudi
arabia
qatar
jordan
unit
kingdom
complet
genom
sequenc
determin
new
viru
close
relat
two
asian
bat
betacoronavirus
lineag
c
make
ncov
first
lineag
c
betacoronaviru
known
infect
human
humantohuman
transmiss
assum
less
extens
compar
sarscov
three
case
saudi
arabia
within
one
famili
sever
healthcar
worker
care
two
case
jordan
classifi
probabl
case
moreov
recent
cluster
case
two
three
case
histori
travel
middl
east
suspect
result
humantohuman
transmiss
within
uk
famili
member
travel
histori
saudi
arabia
pakistan
would
suggest
humantohuman
transmiss
occur
close
contact
set
presum
sporad
natur
appar
unlink
index
case
three
differ
albeit
geograph
proxim
countri
close
relationship
asian
bat
coronavirus
suggest
sourc
ncov
zoonot
despit
limit
inform
new
viru
determin
contrast
sarscov
use
angiotensinconvert
enzym
gain
entri
cell
ncov
use
dipeptidyl
peptidas
function
receptor
find
may
import
requir
thought
partial
respons
pathogen
sarscov
also
serv
one
factor
may
limit
spread
humantohuman
pathogenesi
ncov
could
significantli
differ
previous
studi
coronavirus
abil
predict
whether
viru
like
result
larger
epidem
even
pandem
occur
sarscov
unknown
rapid
identif
therapeut
high
prioriti
current
specif
therapi
vaccin
ncov
result
diseas
sever
high
casefat
rate
clinic
experi
sar
suggest
number
intervent
includ
ribavirin
without
corticosteroid
ribavirin
proteas
inhibitor
interferon
corticosteroid
may
improv
outcom
definit
treatment
regimen
clearli
establish
address
effect
vitro
two
antivir
drug
ribavirin
attempt
identifi
therapeut
approach
immedi
util
clinic
benefit
futur
case
determin
potenti
antivir
effect
ribavirin
ncov
isol
replic
suscept
cell
infect
follow
h
absorpt
infect
cell
treat
either
ribavirin
vero
cell
reduc
cytopathogen
effect
cpe
start
concentr
uml
complet
elimin
cpe
u
ml
figur
ribavirin
reduc
cpe
start
concentr
mgml
complet
elimin
cpe
mg
ml
figur
viral
protein
level
measur
nucleocapsid
protein
express
cell
lysat
also
reduc
presenc
increas
level
reduct
start
uml
figur
respons
ribavirin
treatment
reduct
nucleocapsid
protein
express
observ
mgml
appear
dose
depend
figur
supernat
collect
day
postinfect
subsequ
analys
viral
load
viral
rna
titer
perform
peak
viral
load
infecti
viru
recov
day
sampl
therefor
time
point
use
subsequ
analysi
supernat
collect
day
frequent
lower
viral
load
titer
sampl
collect
day
like
due
extens
cpe
day
sampl
includ
analys
dose
depend
reduct
genom
copi
observ
treatment
reduct
viral
load
uml
reach
reduct
uml
figur
dose
depend
reduct
viral
load
also
observ
ribavirin
treatment
reduct
mgml
reach
reduct
mgml
figur
importantli
correspond
decreas
infecti
viru
also
observ
result
ribavirin
treatment
reduct
viru
titer
occur
uml
increas
reduct
uml
figur
ribavirin
reduct
viru
titer
observ
mgml
reach
reduct
mg
ml
figur
inhibitori
concentr
ic
ribavirin
subsequ
determin
uml
mgml
respect
tabl
ic
reduct
ic
reduct
valu
also
calcul
tabl
signific
find
concentr
ribavirin
requir
effect
inhibit
replic
quit
high
may
therefor
limit
clinic
applic
vero
cell
describ
compar
resist
ribavirin
ineffici
convert
ribavirin
monoand
triphosph
form
therefor
also
assess
sensit
ribavirin
cell
figur
b
base
ic
valu
cell
respons
ribavirin
treatment
tabl
maximum
concentr
test
uml
reduc
infecti
titer
reduct
genom
copi
ribavirin
treatment
mgml
higher
reduc
infecti
viru
detect
threshold
tcid
ml
given
long
histori
combin
use
treatment
hepat
c
combin
ribavirin
treatment
determin
whether
one
compound
would
augment
activ
combin
treatment
vero
cell
lower
threshold
decreas
cpe
note
vero
cell
reduc
uml
mgml
ribavirin
absenc
cpe
uml
mgml
ribavirin
figur
repres
decreas
amount
ribavirin
respect
requir
achiev
reduct
either
treatment
alon
viral
nucleocapsid
protein
express
also
reduc
dose
depend
manner
start
concentr
ribavirin
uml
mgml
respect
figur
reduct
cpe
nucleocapsid
protein
express
also
correl
reduc
viru
genom
copi
titer
administ
ribavirin
ratio
addit
reduct
viru
titer
treatment
alon
figur
ongo
identif
case
ncov
suggest
continu
introduct
viru
human
middl
east
unknown
sourc
given
genet
relationship
hcovemc
bat
coronavirus
one
specul
bat
may
reservoir
viru
howev
addit
host
speci
consid
document
humantohuman
transmiss
close
contact
situat
first
document
mild
case
real
concern
could
observ
tip
iceberg
perhap
start
epidem
regardless
casefat
rate
despit
intens
medic
intervent
therapeut
strategi
urgent
need
despit
signific
increas
research
coronavirus
sinc
discoveri
sarscov
definit
antivir
therapeut
treatment
coronaviru
infect
human
pegyl
interferona
shown
effect
prophylact
treatment
infect
sarscov
cynomolgu
macaqu
less
effect
administ
post
exposur
therapeut
test
antivir
activ
sarscov
higher
order
anim
model
sarscov
mous
model
poli
ic
lc
adenoviru
express
mous
ifna
protect
mice
lethal
diseas
howev
neither
approach
yield
immedi
therapeut
use
human
poli
ic
lc
test
numer
clinic
trial
current
approv
treatment
human
diseas
adenovirusbas
therapi
multipl
complic
factor
preexist
immun
adequ
address
approv
use
human
identifi
potenti
therapeut
approach
combin
ribavirin
either
treatment
alon
reduc
viru
replic
least
much
suscept
cell
line
moreov
combin
efficaci
reach
lower
concentr
thu
combin
may
provid
benefit
treatment
human
vero
cell
display
high
level
resist
activ
ribavirin
thu
also
perform
assay
cell
sensit
ribavirin
observ
much
lower
concentr
previou
vitro
studi
demonstr
sarscov
sensit
ribavirin
variou
class
interferon
b
c
sensit
sarscov
ribavirin
appear
cell
line
depend
concentr
low
mgml
ribavirin
report
effect
unfortun
concentr
higher
peak
serum
concentr
reach
human
approxim
mgml
previous
report
inhibit
growth
sarscov
start
uml
reduct
uml
follow
infect
ifnb
ec
iuml
shown
dose
depend
antivir
effect
studi
report
nearli
reduct
viru
titer
compar
dose
outbreak
sarscov
differ
combin
therapeut
intervent
attempt
howev
none
implement
manner
allow
critic
assess
effect
frequent
administ
therapeut
broadspectrum
antibiot
glucocorticoid
ribavirin
lack
standard
dose
regimen
ribavirin
make
comparison
difficult
howev
low
dose
ribavirin
mgday
therapi
shown
ineffect
like
due
insuffici
plasma
concentr
contrast
use
higher
dose
studi
found
ribavirin
alon
reduc
viral
load
half
patient
combin
viral
proteas
inhibitor
lopinavirritonavir
patient
lower
incid
advers
outcom
unclear
whether
ribavirin
alon
effect
sarscov
synthet
ifna
also
suggest
benefici
patient
unfortun
studi
suffer
confound
use
corticosteroid
dose
vari
among
studi
make
definit
treatment
elus
suggest
combin
interferon
ribavirin
treatment
evalu
ribavirin
result
revers
hemolyt
anemia
complic
typic
occur
follow
longer
treatment
protocol
suggest
shortcours
ribavirin
therapi
acut
infect
ncov
may
signific
complic
mild
anemia
frequent
report
side
effect
ribavirin
treatment
lassa
viru
infect
synergist
effect
ifna
ribavirin
previous
report
vitro
sarscov
felin
infecti
periton
viru
howev
observ
addit
effect
studi
level
ribavirin
requir
inhibit
ncov
replic
must
achiev
human
order
relev
clinic
use
human
interferon
concentr
iuml
observ
intraven
inject
u
mgml
ribavirin
achiev
follow
mg
intraven
dose
ribavirin
alon
shown
antivir
effect
howev
vero
cell
concentr
requir
achiev
benefici
effect
like
higher
achiev
human
combin
inhibitori
concentr
ribavirin
drop
rang
like
achiev
human
suggest
combin
potenti
treatment
option
use
earli
cours
infect
given
prophylact
close
contact
sick
individu
close
contact
transmiss
document
infect
chain
combin
may
improv
clinic
outcom
addit
reduc
viral
load
would
also
like
translat
reduc
viru
shed
thu
reduc
risk
secondari
transmiss
two
drug
current
use
togeth
clinic
combin
therapi
includ
ribavirin
consid
case
patient
manag
new
ncov
case
possibl
prophylaxi
highli
expos
individu
biosafeti
statement
infecti
work
perform
high
contain
facil
rocki
mountain
laboratori
rml
divis
intramur
research
dir
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
work
approv
rml
institut
biosafeti
committe
ibc
biosafeti
level
viru
cell
human
betacoronaviru
emc
kindli
provid
erasmu
medic
center
rotterdam
netherland
vero
african
green
monkey
kidney
rhesu
monkey
kidney
maintain
co
dulbecco
modifi
eagl
media
dmem
supplement
fetal
bovin
serum
fb
uml
penicillin
mgml
streptomycin
hcovemc
subsequ
propag
vero
cell
use
dmem
fb
complet
dmem
antivir
assay
confluent
vero
cell
cultur
plate
costar
corn
ny
infect
triplic
dilut
complet
dmem
moi
follow
h
adsorpt
inoculum
remov
cell
wash
time
dmem
subsequ
complet
dmem
contain
uml
pbl
interferon
sourc
piscataway
nj
andor
ribavirin
mgml
mp
biomed
solon
oh
ad
cell
cell
incub
h
co
humidifi
environ
supernat
remov
aliquot
inactiv
avl
qiagen
germantown
md
viral
load
quantif
remaind
store
subsequ
viru
titrat
supernat
replac
fresh
complet
dmem
contain
andor
ribavirin
supernat
also
collect
h
h
five
day
postinfect
repres
well
photograph
document
cytopath
effect
cpe
cell
subsequ
collect
protein
analysi
sdspage
load
buffer
genom
quantif
rna
avltreat
supernat
extract
nucleospin
viru
core
kit
machereynagel
bethlehem
pa
corbett
xtractor
gene
valencia
ca
quantit
real
time
rtpcr
use
primer
probe
previous
describ
perform
rotorgen
q
qiagen
dilut
seri
viral
rna
base
tcid
equival
use
standard
western
blot
cell
lysat
run
sdspage
gel
transfer
pvdf
ge
healthcar
piscataway
nj
membran
block
nonfat
milk
pb
subsequ
probe
polyclon
serum
dilut
block
buffer
rabbit
immun
inactiv
hcovemc
antirabbit
igg
conjug
horseradish
peroxidas
kpl
gaithersburg
md
use
secondari
dilut
western
blot
develop
pierc
ecl
plu
kit
thermo
rockford
il
infect
assay
tcid
confluent
vero
cell
infect
triplic
dilut
supernat
obtain
antivir
assay
viru
allow
adsorb
h
remov
replac
complet
dmem
cell
incub
co
humidifi
environ
day
cpe
score
tcid
tissu
cultur
infecti
dose
calcul
describ
reed
muench
data
analysi
data
genom
quantif
tcid
assay
analyz
prism
graphpad
softwar
compusyn
combosyncom
